Nivolumab

CAS 946414-94-4 0 current recordsBiologic

Who holds supplier records for Nivolumab? No organisation holds a current US Type II DMF or EU CEP for Nivolumab in the registers PharmaTek covers.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 11 Nov 2026. How we read these records

Cite as: PharmaTek, “Nivolumab: DMF and CEP holder records”, record as of 11 Nov 2026, pharmatek.co.uk/directory/api/nivolumab

Reading the evidence

  • No current DMF or CEP on record

    The covered registers hold no supplier record for this substance. This is not evidence that no one makes it: suppliers may file under another name, sell outside the US and EU, or use an ASMF.

Current records (0)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Nivolumab. Country is the organisation's recorded country, not necessarily the manufacturing site.

Not found in the covered registers (FDA DMF list, EDQM). This is not evidence that no supplier exists.

Need Nivolumab sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Overview

Nivolumab is a human IgG4 monoclonal antibody that acts as a checkpoint inhibitor, specifically targeting the programmed death-1 (PD-1) receptor to enhance anti-tumor immunity. It is primarily used in the treatment of various cancers, including metastatic melanoma, non-small cell lung cancer, and renal cell carcinoma.

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Programmed Death Receptor-1 Blocking Antibody
Mechanism of action
Programmed Death Receptor-1-directed Antibody Interactions

Therapeutic areas

OncologyImmunology

Record history

PharmaTek records which organisations hold a current DMF or CEP for Nivolumab every week, starting 23 Oct 2026. Additions and lapses will appear here from the next weekly release.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.
For suppliers

Do you supply Nivolumab?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.